RenovoRx Files 8-K: Officer/Director Changes & Exhibits
Ticker: RNXT · Form: 8-K · Filed: Mar 27, 2026 · CIK: 0001574094
| Field | Detail |
|---|---|
| Company | Renovorx, INC. (RNXT) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2026 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $450,000, b |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-changes, director-changes, exhibits
TL;DR
RenovoRx 8-K: Leadership changes and exhibits filed 3/27/26.
AI Summary
RenovoRx, Inc. filed an 8-K on March 27, 2026, reporting changes under Item 5.02 concerning the departure of directors or officers, election of directors, appointment of officers, and compensatory arrangements. The filing also includes Item 9.01, which covers financial statements and exhibits, with specific documents like the 8-K form, an exhibit (EX-10.1), and XBRL data provided.
Why It Matters
This filing indicates potential shifts in RenovoRx's leadership or compensation structures, which could impact the company's strategic direction and operational management.
Risk Assessment
Risk Level: medium — Changes in directors or officers can signal internal shifts that may affect company strategy or stability.
Key Numbers
- 43179 — 8-K Form Size (Size of the main 8-K document in bytes)
- 71898 — Exhibit EX-10.1 Size (Size of the attached exhibit in bytes)
- 298609 — Complete Submission Text File Size (Size of the full submission text file in bytes)
Key Players & Entities
- RenovoRx, Inc. (company) — Filer of the 8-K report
- 0001574094 (company) — CIK number for RenovoRx, Inc.
- 2026-03-27 (date) — Filing date of the 8-K report
- Item 5.02 (document_section) — Section detailing director/officer changes and compensation
- Item 9.01 (document_section) — Section detailing financial statements and exhibits
FAQ
What specific changes were made regarding directors or officers on March 27, 2026?
The filing indicates Item 5.02 covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,' but the specific details of these changes are not provided in the summary information.
What is the nature of the exhibit EX-10.1 filed with the 8-K?
The filing lists EX-10.1 as an exhibit, but its specific content is not detailed in the provided summary information, only its file size.
When was the 8-K filing accepted by the SEC?
The 8-K filing was accepted on March 27, 2026, at 07:00:10.
What is RenovoRx, Inc.'s business address and phone number?
RenovoRx, Inc.'s business address is 2570 W. EL CAMINO REAL, STE. 320, MOUNTAIN VIEW CA 94040, and their phone number is 408-800-2649.
What SIC code is associated with RenovoRx, Inc.?
RenovoRx, Inc. is associated with SIC code 2834, which pertains to Pharmaceutical Preparations.
Filing Stats: 828 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2026-03-27 07:00:10
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RNXT Nasdaq Ca
- $450,000, b — pay Dr. Agah annualized base salary of $450,000, based on a minimum of 30 hours worked per
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex10-1.htm (EX-10.1) — 70KB
- ex10-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-26-013080.txt ( ) — 292KB
- rnxt-20260327.xsd (EX-101.SCH) — 3KB
- rnxt-20260327_lab.xml (EX-101.LAB) — 33KB
- rnxt-20260327_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RenovoRx, Inc. Date: March 27, 2026 By: /s/ Shaun R. Bagai Name: Shaun R. Bagai Title: Chief Executive Officer